Stockscreener 앱 받기
3.96
2.46%
-0.10
시간 외 거래:
3.99
0.03
+0.76%
Mannkind Corp 주식(MNKD)의 최신 뉴스
RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating - Insider Monkey
How volatile is MannKind Corporation stock compared to the marketCapitalize on fast-moving stock opportunities - jammulinksnews.com
How MannKind Corporation stock performs during market volatilityCapital Safe Smart Trades - metal.it
What drives MannKind Corporation stock priceFree Stock Selection - PrintWeekIndia
MannKind stock price target lowered to $8 at RBC Capital on model updates - Investing.com Canada
MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association - Insider Monkey
What analysts say about MannKind Corporation stockLightning-fast capital gains - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind Corporation Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright - Defense World
Mannkind director Binder sells $296945 in shares By Investing.com - Investing.com India
Mannkind director Binder sells $296945 in shares - Investing.com
H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com
What makes MannKind Corporation stock price move sharplyLow Risk Scalping Alerts - Newser
Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser
High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance
Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Insider Monkey
13 Best Healthcare Stocks to Buy Under $10 - Insider Monkey
Wedbush Remains Bullish on MannKind Corporation (MNKD) - Insider Monkey
13 Stocks Under $5 With High Upside Potential - Insider Monkey
MannKind Corp stock hits 52-week low at $3.63 - Investing.com
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000 Value Index - MarketScreener
Today In SCV History: June 27, 2014 – Valencia Company Given FDA Approval For Inhaled Insulin - KHTS Radio
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Insider Monkey
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com UK
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia
MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
1.32%
1.06%
자본화:
|
볼륨(24시간):